Utah Medical Products Inc. (UTMD) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, Utah Medical Products Inc. (NASDAQ: UTMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $66.80 (-2.96% 1D, market cap $212.7M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, UTMD ranks #159 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), UTMD carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 57.1%, and ROIC of 26.9%. By comparison, PROF (Profound Medical Corp.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $214.1M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
Per UTMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000706698), Utah Medical Products Inc. generated $38.5M in revenue (-5.8% YoY), $0 in net income, and $14.3M in free cash flow against $122.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (57% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 37.2% FCF Margin ($14.3M FCF) & 57.1% Gross Margin
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
Even with a 63/100 (C) score, UTMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 54.6% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.90) or 200D SMA ($68.07) invalidates the momentum regime and cuts Target Base ($68.30) toward Bear Floor ($53.27).
Utah Medical Products Inc. (UTMD) dropped -2.96% to $66.80, trading at 57% of its 52-week range ($53.66 – $76.89). Solid 57% profit margin (27% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
In a recent SEC filing, it was revealed that Kevin L Cornwell, Chairman at Utah Medical Products (NASDAQ:UTMD), made a noteworthy insider purchase on October 29,. What Happened: In a Form 4 filing on Thursday with the
SALT LAKE CITY, UT / ACCESS Newswire / October 29, 2026 / On September 24, (Nasdaq:UTMD) offered to purchase up to 650,000 shares of its common stock at $75. The issuer Tender Offer expired Tuesday October 27.
SALT LAKE CITY, UT / ACCESS Newswire / October 29, 2026 / (NASDAQ:UTMD) offered to purchase up to 650,000 shares of its common stock at $75. The issuer Tender Offer expired Tuesday October 27.
Utah Medical's Q3 earnings per share rise 7% year over year despite a 12.1% revenue decline, aided by lower operating expenses. Management expects a smaller revenue decline for full-year 2026.
Utah Medical Products came into this Q3 2026 report with a mixed reputation. The business throws off high margins and a steady dividend, yet five year earnings have trended lower. The latest numbers show Q3 basic earning
MIDVALE, Utah (AP) — MIDVALE, Utah (AP) — Utah Medical Products Inc. (UTMD) on Thursday reported net income of $2.
SALT LAKE CITY, UT / ACCESS Newswire / October 22, 2026 / (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2026 financial results that include changes from the prior year's same period
Utah Medical Products (NASDAQ:UTMD) reported quarterly earnings of $0.88 per share. This is a 7.32 percent increase over earnings of $0.82 per share from the same period last year. The company reported $8.621 million
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -5.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on UTMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for UTMD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Utah Medical Products Inc. (UTMD) ranks #159 by composite RQD confidence (63/100, grade C) and #566 by equity capitalization ($212.7M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| UTMD
ACTIVE
Utah Medical Products Inc. | C | 63/100 | — | 57.1% | 26.9% | -2.96% | $212.7M | Benchmark Subject |
| PROF Profound Medical Corp. | D | 47/100 | — | 70.8% | -35.0% | +1.38% | $214.1M | /prof-vs-utmd → |
| KTWO K2 Capital Acquisition Corporation Class A Ordinary Share | D+ | 53/100 | — | — | — | +0.30% | $202.8M | /ktwo-vs-utmd → |
| PDEX Pro-Dex Inc. | D | 51/100 | 22.2x | 29.3% | 23.2% | -2.52% | $199.2M | /pdex-vs-utmd → |
| STIM Neuronetics Inc. | E | 31/100 | — | 48.5% | -35.0% | +5.31% | $181.3M | /stim-vs-utmd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Utah Medical Products Inc. (UTMD) reported GAAP revenue of $38.5M (-5.8% vs. FY2024 revenue of $40.9M , and -23.3% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $14.7M, and free cash flow of $14.3M (-1.9% YoY). On the balance sheet, UTMD closed FY2025 with $122.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $38.5M | $0 | $14.7M | $14.3M | $122.5M | — |
| FY2024 (FY) | 2024-12-31 | $40.9M | $0 | $14.8M | $14.6M | $122.5M | — |
| FY2023 (FY) | 2023-12-31 | $50.2M | $0 | $22.3M | $22.3M | — | — |
As of 2026-11-01, Utah Medical Products Inc. (NASDAQ: UTMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $66.80 (-2.96% 1D, market cap $212.7M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, UTMD ranks #159 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), UTMD carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 57.1%, and ROIC of 26.9%. By comparison, PROF (Profound Medical Corp.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $214.1M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
Per UTMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000706698), Utah Medical Products Inc. generated $38.5M in revenue (-5.8% YoY), $0 in net income, and $14.3M in free cash flow against $122.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (57% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
UTMD last traded at $66.80 (-2.96% on volume of 32,588 shares), positioning the stock -8.37% below its 50-day simple moving average ($72.90) and -1.87% below its 200-day simple moving average ($68.07). Across its 52-week range of $53.66 to $76.89, UTMD sits at the 56.6% percentile with a 14-day RSI of 30.1 (OVERSOLD (<32)) and an implied next-earnings move of ±3.7% ($64.33 to $69.27).
Why UTMD Stock dropped -2.96% Today — RQD Quant Desk Flash. Solid 57% profit margin (27% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.